Purpose Our objective was to determine the impact of initial 18 F-FDG PET/CT (PET/CT)
staging on clinical stage and the management plan and the prognostic value of PET/CT in …

We investigated the incremental management impact and prognostic value of staging with
18F-FDG PET/CT in patients with non–small cell lung cancer (NSCLC) being considered for …

Survival of lung cancer patients remains poor despite increasingly aggressive treatment.
Conventional staging has well-described limitations. 18F-FDG PET has been shown to …

Objective To investigate whether differences in thoracic tumour staging between 18 F-FDG
PET/CT and PET/MR imaging lead to different therapeutic decisions in Non-Small Cell Lung …

Introduction Positron emission tomography (PET) has improved the accuracy of staging non-
small cell lung cancer (NSCLC), although some early-stage patients will still relapse. The …

Objective In recent years, positron emission tomography/magnetic resonance imaging
(PET/MRI) has been clinically used as a method to diagnose non-small cell lung cancer …

BACKGROUND: The treatment of patients with nonsmall cell lung cancer (NSCLC) is
determined by the stage. We evaluated the accuracy of staging using integrated positron …

Purpose: The aim of this study was to analyse the impact of FDG-PET staging on treatment
results of neo-adjuvant radiochemotherapy in patients with advanced non-small cell lung …

Background and purpose Pre-and mid-radiotherapy FDG-PET metrics have been proposed
as biomarkers of recurrence and survival in patients treated for stage III non-small cell lung …

PURPOSE: To determine the accuracy of dual-modality positron emission tomographic
(PET)–computed tomographic (CT) imaging, as compared with PET alone and CT alone, in …